INTRODUCTION — Depression and suicide have been reported in association with multiple sclerosis (MS). Some studies show that interferon beta may increase the depression rate. We report a case of depression and suicidal ideation in coincidence with the start of increased doses of interferon beta-1a and their complete reversal following the drug withdrawal. The patient was a 21-year-old man with MS and no past history of affective disorders who was given interferon beta-1a in the dose of 11 µg three times per week. As a new relapse occurred the dose of interferon beta-1a was increased to 22 µg three times a week. The patient then observed increased worry, irritability and a sense of discouragement as well as recurring suicidal thoughts. His mood was rapidly restored following interferon beta-1a withdrawal. This case suggests that patients with MS may develop depression and suicidal thoughts when treated with high doses of interferon beta-1a.

KEYWORDS: multiple sclerosis, interferon beta-1a, depression, suicidal ideation.

Although affective symptoms in multiple sclerosis (MS) have been noticed since its clinical characterization by Charcot only in the last two decades more detailed studies dealing with their prevalence, causality, profile and treatment have been carried out. Depressive symptoms of sufficient severity and duration to warrant a diagnosis of major depression affect 25 to 50% of MS patients during the course of disease. This rate is higher than that found in both the general population and patients with other disabling neurological conditions such as amyotrophic lateral sclerosis, temporal lobe epilepsy, muscular dystrophy and spinal cord trauma.

The clinical heterogeneity of depression, which includes symptoms of a variety of intensity such as transient changes in mood, adjustment disorders to life events, dysthymia, and major depression, as well as their overlapping with MS more well-defined somatic symptoms such as fatigue and sleeplessness might make one supposes that the frequency of depression has been overestimated. Nevertheless some studies have shown that, even when these associated somatic symptoms are appropriately controlled, depression in MS patients remains highly prevalent. In addition to that, major depression in these patients is mainly characterized by anger, irritability and worry rather than apathy, withdrawal, feeling of guilt and worthlessness, usually found in uncomplicated major depression. Likewise, suicide, attempted suicide and suicidal ideation occur more frequen-
fatigue, sleep or appetite disturbance. Repeated neurological examination and recurring suicidal thoughts. He denied sease, increased irritability, feeling of anger, sense of dis- 

Later he started complaining of marked worry about his disease; moderately pale and there were upper limb dysmetria, decreased tactile and pain sensation in the upper and lower extremities, absent vibration sense in the lower limbs and decreased position sense in the toes. The gait was normal. A new brain MRI disclosed T2-hyperintense lesions in the corpus callosum and white matter of the frontal lobes, right temporal lobe, right parietal lobe and both occipital lobes. A cerebrospinal fluid examination disclosed 7 lymphocytes per cubic millimeter, protein 40 mg%, glucose 70 mg% and IgG index 0.92. The patient was given IV methylprednisolone and was started on subcutaneous interferon beta-1a. The dose was increased to 22 µg three times per week. A few weeks later he started complaining of marked worry about his disease, increased irritability, feeling of anger, sense of discouragement and recurring suicidal thoughts. He denied fatigue, sleep or appetite disturbance. Repeated neurological examination and brain MRI study failed to reveal any new finding. Interferon beta-1a withdrawal rapidly restored his mood. He has been now on glatiramer acetate for over six months and depressive symptoms and suicidal ideation have not recurred.

**DISCUSSION**

The present case highlights the association between MS and depressive symptoms and may even suggest that major depression and suicidal ideation were caused or triggered by the increase in interferon beta-1a dose. The patient had no previous or family history of depression and had been adequately coping with his disease until the dose of interferon beta-1a was increased to 22 µg three times per week. Additional evidences supporting the relationship of depressive symptoms to the increased dose of interferon beta-1a include absence of change in the neurological disability status as measured by the EDSS at the time of the onset of depression, absence of fatigue as an associated symptom, no new lesions on a repeated brain MRI, and the complete disappearance of the depressive symptoms immediately following the drug withdrawal.

There are several convincing trials demonstrating that interferon beta and more recently glatiramer acetate decrease the frequency of MS relapses by approximately 30%, significantly reduce the burden on total lesion load in the brain and show a trend toward a delay in the progression of disability. Although some investigators have already shown that increases in depressive symptoms to the increased dose of interferon beta-1a include absence of change in the neurological disability status as measured by the EDSS at the time of the onset of depression, absence of fatigue as an associated symptom, no new lesions on a repeated brain MRI, and the complete disappearance of the depressive symptoms immediately following the drug withdrawal.

There are several convincing trials demonstrating that interferon beta and more recently glatiramer acetate decrease the frequency of MS relapses by approximately 30%, significantly reduce the burden on total lesion load in the brain and show a trend toward a delay in the progression of disability. Although some investigators have already shown that increases in depressive symptoms to the increased dose of interferon beta-1a include absence of change in the neurological disability status as measured by the EDSS at the time of the onset of depression, absence of fatigue as an associated symptom, no new lesions on a repeated brain MRI, and the complete disappearance of the depressive symptoms immediately following the drug withdrawal.

There are several convincing trials demonstrating that interferon beta and more recently glatiramer acetate decrease the frequency of MS relapses by approximately 30%, significantly reduce the burden on total lesion load in the brain and show a trend toward a delay in the progression of disability. Although some investigators have already shown that increases in depressive symptoms to the increased dose of interferon beta-1a include absence of change in the neurological disability status as measured by the EDSS at the time of the onset of depression, absence of fatigue as an associated symptom, no new lesions on a repeated brain MRI, and the complete disappearance of the depressive symptoms immediately following the drug withdrawal.

There are several convincing trials demonstrating that interferon beta and more recently glatiramer acetate decrease the frequency of MS relapses by approximately 30%, significantly reduce the burden on total lesion load in the brain and show a trend toward a delay in the progression of disability. Although some investigators have already shown that increases in depressive symptoms to the increased dose of interferon beta-1a include absence of change in the neurological disability status as measured by the EDSS at the time of the onset of depression, absence of fatigue as an associated symptom, no new lesions on a repeated brain MRI, and the complete disappearance of the depressive symptoms immediately following the drug withdrawal.

There are several convincing trials demonstrating that interferon beta and more recently glatiramer acetate decrease the frequency of MS relapses by approximately 30%, significantly reduce the burden on total lesion load in the brain and show a trend toward a delay in the progression of disability. Although some investigators have already shown that increases in depressive symptoms to the increased dose of interferon beta-1a include absence of change in the neurological disability status as measured by the EDSS at the time of the onset of depression, absence of fatigue as an associated symptom, no new lesions on a repeated brain MRI, and the complete disappearance of the depressive symptoms immediately following the drug withdrawal.
gest that physicians should closely monitor their patients with recent history of depressive symptoms, regardless of their current mental status, as the risk of major depression is increased in the first months of treatment.

Previous studies have documented depressive symptoms in patients receiving high-dose interferon alpha as treatment for malignant melanoma and chronic hepatitis C. Suicidal ideation and many cases of suicide have been also reported. Depression and fatigue were found to be related significantly to discontinuation of treatment both in patients receiving alpha or beta interferon. During the first three months of interferon alpha therapy for malignant melanoma 45% of the patients developed major depression, and more than one third of them had to discontinue treatment. Pretreatment with the antidepressant paroxetine significantly reduced the incidence of major depression and helped patients to remain on treatment. Similarly, in a series of 85 patients treated with interferon beta-1a for MS Mohr et al. observed new or increased depression in 41% of them within six months of therapy. They also noticed that antidepressant drugs and psychotherapy helped patients with depression to remain on treatment.

The mechanisms by which interferon beta causes depression are still unclear. It is well known that interferon alpha induces the production of pro-inflammatory cytokines such as tumor necrosis factor-α, interleukin-1 and interleukin-6, all of which are potent inducers of sickness behavior and neurotoxic effects. It is likely that similar effects can be also produced by interferon beta. An immune dysregulation has been recently associated with mood and cognitive changes in MS.

Anatomical correlates of depression in MS patients have not been well defined. Although some investigators have failed to demonstrate an association between the presence of MRI abnormalities and affective symptoms, others have found association between depression and temporal lobe involvement in right parietal region, the left frontal lobe, the left arcuate fasciculus or the total lesion load. Additionally, a disconnection between subcortical and cortical areas connected to the limbic system has been proposed. In a recent comparative study of lesion patterns in 31 patients with MS and depression as opposed to 47 MS patients without depression, Berg et al. found that the most significant difference was observed in the temporal lobes with depressed patients having a higher lesion load than non-depressed patients. Differences were also significant for lesion load in the right parietal lobe, and a trend was found for lesions in the right frontal lobe, total lesion load and lesion load of the cerebellum. They emphasize that the areas with higher lesion load are projection areas of the basal-limbic system, giving support to Sabattini et al.’s suggestion that depression in MS could be caused by a disconnection of subcortical and cortical areas involved in limbic system functions. Significant correlation was seen between severity of depression and the lesion load in the temporal lobes, more marked in the right side. Transcranial sonography provided no evidence for structural abnormalities of the ponto-mesencephalic midline as has been seen in patients with unipolar depression as well as in Parkinson’s disease patients with depression.

As depression adds morbidity to MS, increased risk of suicide may turn it still more dramatic. Since Kahana et al. in 1971 reported that 3% of his 295 patients committed suicide in contrast with 0.1% rate observed in the general population a widespread concern has arisen. In a study of 5525 MS patients Stenager et al. reported a significantly elevated suicide rate, with males and patients under 30 years most at risk. In a study on causes of death in 3126 MS patients Sadovnick et al. found suicide accounting for 15% of all ascertained deaths. A reduction in serotonergic activity has been demonstrated in MS and non-MS patients who were depressed and committed suicide and a decreased nocturnal secretion of melatonin which derives from serotonin has been found in MS patients with suicidal ideation or intent.

Early identification of depressive symptoms in MS patients or identification of which patients are more vulnerable to depression during interferon beta treatment could provide physicians with efficient therapy strategies. Antidepressant agents, such as tricyclics, fluoxetine and selective serotonin-reuptake inhibitors, may be effective in the prophylaxis and treatment of depressive symptoms in MS and interferon-associated depression. Other forms of treatment include psychotherapy and cognitive-behavior therapy.

Although there is no consensus regarding withdrawal of interferon beta when MS patients develop depression, the suicidal ideation in our patient was worrisome enough to prompt a change in the therapy. So far studies on glatiramer acetate in MS have not shown any deleterious effect in mood making it a safer drug in MS patients with affective disorders.
or in cases like ours, of interferon therapy-related depression. Physicians prescribing interferon beta for MS treatment should be alert to the occurrence of depressive symptoms and suicidal thoughts in their patients which may add suffering to this disabling condition.

REFERENCES


